Institut Gustave Roussy

Institut National De La Sante Et De La Recherche Medicale

Université Paris-Saclay

Institut National De Recherche Pour L'agriculture, L'alimentation Et L'environnement

Other

Centre National De La Recherche Scientifique

Transgene S.a.

Institut National De La Sante Et De La Recherche Medicale (Inserm)

Université De Rennes

Institute Curie

Institut De La Recherche Agronomique

Insitut National De Recherche Pour L'agriculture, L'alimentation Et L'environnement (Inrae)

Institut National De La Recherche Agronomique

Université Paris—sud

Inserm (Institut National De La Sante Et De La Recherche Medicale)

Laurence Zitvogel

Guido Kroemer

Sebastian Amigorena

Fabrice Andre

Patricia Lepage

Jean-Christophe Sabourin

Bertrand Routy

Armelle Regnault

Ivo Gomperts Boneca

Emmanuelle Le Chatelier

Nicolas Delahaye

Sophie Viaud

Romain Daillere

Eric Vivier

Laetitia Fend

Lionel Apetoh

Dalil Hannani

Theocharis Panaretakis

Caroline Robert

Graça Raposo

Nadine Fernandez

Nathalie Chaput-Gras

Gra&ccedil;a Raposo

Maria Paula Roberti

Yuting Ma

Xavier Preville

Oliver Kepp

Marie Vetizou

The invention relates to the prognosis and treatment of colon cancer. In particular, the present invention concerns the role of intestinal microbiota in the anticancer immune response elicited by ileal enterocytes succumbing to apoptosis, and provides immunogenic compositions for treating colorectal cancer (CRC), as well as signatures for prognosing CRC evolution.

Bacterial and cell compositions for the treatment of colorectal cancer and methods for assessing a prognosis for patients having the same

The invention relates to gut microbiota profiles associated with response or resistance to treatments with ICB, in particular with anti-PD1 or anti PD-L1 or anti-PD-L2 antibodies. In particular, the invention pertains to a theranostic method for identifying good responders, to whom an anti-PD1 or anti PD-L1 or anti-PD-L2 can be administered, while a pre-treatment based on FMT and/or immunogenic probiotics is recommended to bad responders exhibiting a dysbiosis. In particular, the present invention pertains toas the main commensal species distinguishing responders from progressors and its use alone or withfor the treatment of antibiotics or gut repertoire insufficiency-associated dysbiosis.

Microbiota composition, as a marker of responsiveness to anti-PD1/PD-L1/PD-L2 antibodies and use of microbial modulators for improving the efficacy of an anti-PD1/PD-L1/PD-L2 AB-based treatment

The present invention relates to the field of probiotic adjuvantization of anticancer treatments. In particular, the present invention concerns immunogenic sequences from a prophage present in bacteria identified as efficient adjuvants of cancer treatments. The invention provides bacterial compositions expressing immunogenic sequences from this prophage, immunogenic compositions comprising such sequences and methods using sequences from this prophage, for increasing the anticancer armamentarium.

Immunogenic sequences from a phage tail length tape measure protein, bacteria expressing the same and their use in treating a cancer

Microbiota composition, as a marker of responsiveness to anti-PD1/PD-L1/PD-L2 antibodies and use of microbial modulators for improving the efficacy of an anti-PD1/PD-L1/PD-L2 ab-based

The present invention provides methods for determining if a patient is likely to benefit from a cancer treatment, by determining if said patient has a gut dysbiosis with an over representation of certain bacterial species. The present invention also provides probiotic strains to improve the efficacy of a cancer treatment, especially chemotherapy, in patients in need thereof.

Microbiota composition, as a marker of responsiveness to chemotherapy, and use of microbial modulators (pre-, pro- or synbiotics) for improving the efficacy of a cancer treatment

The present invention provides a combination comprising at least an oncolytic virus and one or more immune checkpoint modulator(s) for use for the treatment of a proliferative disease such as cancer. It also relates to a kit comprising an oncolytic virus and one or more immune checkpoint modulator(s) in separate containers. It also concerns a pharmaceutical composition comprising effective amount of an oncolytic virus and one or more immune checkpoint modulator(s).

Combination of oncolytic virus with immune checkpoint modulators

The present invention relates to a method of assessing, predicting or monitoring the sensitivity of a subject having a tumor or cancer to an immunotherapeutic molecule acting on the subject's T cells, to a method of selecting an appropriate treatment of cancer, to a method of screening or identifying a compound suitable for improving the treatment of a cancer, and to the use of corresponding kits. The method of predicting or monitoring the sensitivity of a subject having a tumor to an immunotherapeutic molecule acting on the subject's T cells typically comprises a step a) of determining, in a biological sample from said subject, the expression level of soluble CD25 (sCD25) and, when the expression level is determined, a step b) of comparing at least said expression level to a reference expression level, thereby assessing whether the subject having a tumor is responsive or resistant to the immunotherapeutic molecule.

Methods for predicting the sensitivity of a subject to immunotherapy

The present invention relates to a method of assessing a favorable or, on the contrary, an unfavorable prognosis of a cancer in the subject, which method comprises detecting the presence of a mutated Natural Cytotoxicity-triggering Receptor 3 (NCR3) nucleic acid, an abnormal relative amount of at least one particular Natural Killer p30 (NKp30) RNA transcript isoform, and/or an abnormal Natural Killer p30 (NKp30) expression or activity of at least one particular NKp30 protein isoform in a sample from the subject, the presence of mutated NCR3 nucleic acid, abnormal relative amount of at least one particular NKp30 RNA transcript isoform, or abnormal expression or activity of at least one particular NKp30 protein isoform being indicative of the prognosis of cancer in the subject.

Natural killer p30 (NKp30) dysfunction and the biological applications thereof

The present invention relates to a method of predicting or monitoring the sensitivity of a subject having a tumor to a chemotherapy, a method of selecting an appropriate chemotherapeutic treatment of cancer, a method of screening or identifying a compound suitable for improving the treatment of a cancer, and corresponding kits. The method of predicting or monitoring the sensitivity of a subject having a tumor to a chemotherapy typically comprises a step a) of determining, in a biological sample from said subject, the presence, absence or expression level of at least one of a soluble B7H6 (sB7H6 or sB7-H6) and a soluble MIC (sMIC) and, when the expression level is determined, a step b) of comparing said expression level to a reference expression level, thereby assessing or monitoring whether the subject having a tumor is responsive or resistant to the chemotherapy.

Methods of treating gastrointestinal sarcoma patients depending on their sB7H6 serum level

The present invention relates to the fields of genetics, immunology and medicine. The present invention more specifically relates to in vitro or ex vivo methods for determining the susceptibility to a cancer treatment of a subject having a tumor. These methods comprise a step of determining the ability of the treatment, of the subject and/or of the tumor to induce an anticancer immune response, the inability of at least one of the treatment, the subject and the tumor to induce an anticancer immune response being indicative of a resistance of the subject to the therapeutic treatment of cancer. Inventors in particular identify genes specific of a human subject or of cancerous cells which can be used to predict or assess the sensitivity of a subject to a treatment of cancer. The invention also relates to particular compounds capable of activating or enhancing the immune system of a particular subject, when the subject is exposed to a therapeutic treatment of cancer or before such an exposition. It further relates to uses of such compounds, in particular to prepare a pharmaceutical composition to allow or improve the efficiency of a therapy of cancer in a subject in need thereof. The present invention in addition provides kits, methods for selecting a compound of interest, as well as pharmaceutical compositions and uses thereof.

Method of treatment for immunogenic treatment resistant cancer

Compounds and uses thereof to induce an immunogenic cancer cell death in a subject

The present invention relates to an in vitro method of assessing the sensitivity of a subject to a treatment of cancer, which method comprises detecting the presence of a mutated Toll Like Receptor 4 (TLR4) nucleic acid or an abnormal TLR4 protein expression or activity in a sample from the subject, the presence of said mutated TLR4 nucleic acid or abnormal TLR4 expression or activity being indicative of a resistance to said treatment. The invention further provides compounds for treating or preventing a cancer in a subject having a mutated TLR4 nucleic acid or an abnormal TLR4 protein expression or activity.

Toll like receptor 4 dysfunction and the biological applications thereof

The present invention relates generally to the fields of genetics and medicine. More specifically, the present invention relates to improved methods of treating cancers using a TLR3 agonist, by assessing the expression of a TLR3 receptor by cancer cells.

Treatment of cancer using TLR3 agonists

The present invention relates to a method for determining the susceptibility of a patient tumor cell to a cancer treatment, which method comprises the detection or measure of CRT, KDEL receptor and/or ERp57 on the surface of a tumor cell.

Compounds regulating calreticulin, KDEL receptor and/or Erp-57 cell surface exposure and uses thereof to evaluate the efficiency of a cancer treatment

Growing community of inventors

Paris, France

Laurence Zitvogel